Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study

By N. Sattar, A. Gaw, O. Scherbakova, Ian Ford, D. O'reilly, S. Haffner, C. Isles, P. Macfarlane, C. Packard, S. Cobbe and 1 more. Circulation, 2003

1,607 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/00e403c692837ac226164871e3214adf5ec658dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. P. Zimmet
2. J. Shaw
3. E. Ford
4. A. Cameron
5. G. Kaltsas
6. E. Kassi
7. Panagiota Pervanidou
8. George P. Chrousos

In Epidemiology

1. P. Zimmet
2. E. Ford
3. Christian K. Roberts
4. R. J. Barnard
5. J. Shaw
6. T. Tamimi
7. R. Lopez
8. R. Kahn

In Surgery

1. P. Zimmet
2. J. Shaw
3. A. Cameron
4. R. Kahn
5. Christian K. Roberts
6. R. J. Barnard
7. E. Ford
8. E. Ferrannini

Citations in the corpus

• The metabolic syndrome: time for a critical appraisal (2005, positive): “[73] showed that the metabolic syndrome was not a significant predictor of coronary heart disease when adjusted for its component factors in a multivariate model.”
• Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. (2005, methodology): “When three studies (13,16,17,21,23,24) that used the modified NCEP definition were added, the fixed-effects estimate was 1.”
• Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. (2005, methodology): “Finally, because waist circumference was not available, we used BMI as a proxy to classify individuals with obesity, similar to other studies.(7,17,20) Despite these limitations our findings are consistent with those of previous reports showing MetS to be a stronger predictor of diabetes than CHD(7,”
• Metabolic syndrome: definitions and controversies (2011, result): “Currently used criteria to define MetS Historically, Reaven was the first to put forward the concept of ‘syndrome X’, (which he later renamed MetS), hypothesizing that it was a central feature in the development of CHD and DMT2, mainly through target tissue resistance to insulin action [1].”
• C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. (2007, neutral): “…by current criteria who have hsCRP (cid:2) 3 mg/l are at higher risk for future cardiovascular events and diabetes compared with those with metabolic syndrome who have hsCRP (cid:1) 1 mg/l, a risk relationship almost identical to that for hsCRP among individuals without metabolic syndrome (24–26).”